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OBJECTIVES The goal of this study was to evaluate the effects of acute and chronic amiodarone on
activation patterns during ventricular fibrillation (VF), ventricular effective refractory period
(VERP) and defibrillation threshold (DFT).
BACKGROUND Acute and chronic amiodarone may act through different mechanisms.
METHODS The VERP, VF activation patterns and DFT were determined in 24 dogs. Twelve dogs
received acute intravenous amiodarone (10 mg/kg, n  6) or saline (n  6), and 12 dogs
received chronic oral amiodarone (20 mg/kg/day, n  6) or placebo (n  6). Epicardial VF
activation patterns were recorded with 504 electrodes. Quantitative descriptors of VF were
calculated.
RESULTS The DFT was unchanged by acute or chronic amiodarone. Although chronic amiodarone
significantly extended the VERP, acute amiodarone did not. In the mapped region, acute and
chronic amiodarone decreased the number of VF wavefronts by 42% and 60%. Acute
amiodarone decreased conduction block by 22%, while chronic amiodarone increased block by
41% but decreased wave fractionation by 50%. Both chronic and acute amiodarone increased
the size of the core of re-entrant circuits and decreased the incidence of re-entry by 44% and
57%; however, chronic amiodarone increased wavelength, while acute amiodarone did not.
CONCLUSIONS Neither acute nor chronic amiodarone change the DFT. While both acute and chronic
amiodarone decrease the number of wavefronts, decrease the incidence of re-entry and
increase the size of re-entrant cores in the mapped region during VF, they achieve these
antiarrhythmic effects through different electrophysiologic mechanisms. Chronic amiodarone
prolonged the VF cycle length and slowed conduction velocity, indicating it increased the
wavelength and/or the excitable gap. (J Am Coll Cardiol 2002;40:375–83) © 2002 by the
American College of Cardiology Foundation
Clinically, the electrophysiologic effects of amiodarone dif-
fer significantly when it is given chronically by mouth
compared with an acute intravenous dose (1), a difference
for which the mechanisms remain unexplained. Amioda-
rone is commonly prescribed for patients with an implant-
able defibrillator who receive frequent shocks for ventricular
arrhythmias or patients with out-of-hospital cardiac arrest
due to refractory ventricular arrhythmias, in whom amioda-
rone has been shown to increase survival to hospital admis-
sion (2). Potential effects of amidarone on defibrillation
have become increasingly important with the introduction
and success of the implantable cardioverter defibrillator.
However, previous studies of the effect of amiodarone on
the defibrillation threshold (DFT) have yielded conflicting
results (3–5).
The wavelength (6,7), incidence of conduction block (8),
number and size of activation fronts and number, duration
and core size of re-entrant circuits are important parameters
for characterizing the effects of antiarrhythmic drugs for
either atrial or ventricular fibrillation (VF). Because it is
difficult and tedious to study these numerous parameters
during VF solely by visual analysis, we recently developed
automated methods to quantify VF activation patterns
(9,10). These methods have been used to detect how
activation patterns differ in the right and left ventricles (11)
and how they are altered by heart failure (12). The detection
of activation pattern differences during VF before and after
antiarrhythmic drug administration should help us to fur-
ther understand the antifibrillation mechanisms for those
drugs. In this study, we quantitatively evaluated the changes
in VF activation patterns caused by acute and chronic
amiodarone administration to determine if they achieve
their antiarrhythmic effects through the same or different
mechanisms.
METHODS
All animals were managed in accordance with the guidelines
established by the American Heart Association on Research
Animal Use (13), and protocols were approved by the
University of Alabama at Birmingham Institutional Animal
Care and Use Committee.
Animal preparation. Based on the route of amiodarone
administration, the animals were divided into two groups:
1)acute and 2) chronic. The same methods for preparation,
ventricular effective refractory period (VERP) measurement,
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DFT measurement and electrical mapping were used in
both groups. Mongrel dogs 24 to 36 kg (30  4 kg, mean
 SD) were anesthetized with 25 mg/kg intravenous
thiopental sodium and maintained with 2% to 3% isoflurane
in 100% oxygen delivered by mechanical ventilation. Succi-
nylcholine was initially given at a dose of 1 mg/kg and
followed by 0.25 to 0.5 mg/kg at about 20 min intervals to
decrease skeletal muscle movement induced by defibrillation
shocks. Lactated Ringers solution was continuously infused
intravenously (2 to 5 ml/kg/min). Core body temperature,
arterial blood gas values and serum electrolytes were main-
tained within normal physiologic ranges throughout the
experiment. Blood pressure and the lead II surface electro-
cardiogram (ECG) were displayed on a monitor.
Measurement of refractory period. The VERP was deter-
mined using an incremental S1-S2 pacing protocol from a
pair of bipolar electrodes inserted into the subepicardium for
the acute group and from the tip and right ventricle
electrodes (0094 Endotak, Guidant, St. Paul, Minnesota)
for the chronic group. Both S1 and S2 stimuli (2 ms
duration) were given at twice diastolic threshold. The S1-S1
interval was 300 ms (10 beats), and the initial S1-S2 interval
was 140 ms. The S1-S2 interval was increased in 10-ms
increments until the S2 stimulus captured the ventricles on
the ECG. Then the S1-S2 interval was reset to 10 ms less
than this interval and was increased in 2-ms increments
until S2 again captured the ventricles. This procedure was
repeated three times, with 2 min between each determina-
tion. The longest S1-S2 interval failing to capture in any of
the three trials was defined as the VERP. We used VF cycle
length as an index of the effective refractory period (ERP)
during VF (14).
DFT determination. In the chronic group, the DFT was
determined for an SVC electrode and a right ventricular
electrode (0094 Endotak, Guidant). Ventricular fibrillation
was induced with 30-V, 60-Hz alternating current through
the sensing/pacing electrode on the defibrillation catheter.
After 20 s of VF, a biphasic shock (6/4 ms) was given. The
leading edge voltage of the first shock was 400 V for the first
animal and was the mean DFT from previous animals for
the following animals. Depending on the success or failure
of the shock, the leading edge voltage was decreased or
increased by 40 V, respectively. The transition from failure
to success or success to failure was recorded as the first data
point. The up-down algorithm was continued until the
third reversal of success to failure or failure to success was
reached. The DFT was determined by averaging the four
shock strengths that formed the three reversals (10). At least
5 min elapsed after every VF episode to allow blood pressure
and heart rate to return to normal. The DFT determination
protocol used for the acute group was the same as in the
chronic group except that the right ventricular electrode was
exchanged for an epicardial patch (10 mm in diameter) on
the left ventricular apex.
Mapping. The heart was exposed through a median ster-
notomy and supported in a pericardial sling. A 504-
electrode (24  21) plaque was sutured to the anterior right
ventricular epicardium with slight overlap onto the anterior
left ventricular epicardium. The electrodes were 2 mm apart
and, in total, covered 20.16 cm2, which is about 20% of the
ventricular surface. The ground reference for the unipolar
recordings was attached to the right leg.
Amiodarone administration. In the acute group, after
baseline testing, six animals received a loading dose of
amiodarone (10 mg/kg in 5 cc dimethyl sulfoxide [DMSO])
followed by a maintenance infusion of 0.03 mg/kg/min,
which has been reported to cause a steady-state plasma
concentration (15). In another six control animals, DMSO/
saline was administered instead of amiodarone. Electro-
physiologic measurements were repeated after 15 min of
infusion of amiodarone or DMSO/saline.
In the chronic group, 12 dogs were randomly assigned
into two subgroups. Each animal underwent closed-chest
baseline VERP and DFT testing on day 1 of the study via
transvenous electrodes. After testing on day 1 and through-
out the subsequent 29 days, six dogs were administered
amiodarone 20 mg/kg/day in divided oral doses (5). In the
other six dogs, a placebo was administered instead of
amiodarone. On day 30 of the study, the animals again
underwent closed-chest electrophysiologic measurements,
followed by open-chest mapping of VF. The investigators
were blinded to whether the dogs received amiodarone or
placebo.
Amiodarone concentrations. A 6-ml blood sample was
obtained at the end of the study from the chronic amioda-
rone animals and three control animals. The samples were
centrifuged, and serum was frozen at 20°C until analysis.
A high performance liquid chromatographic technique was
used to quantitate amiodarone (16). The limit of quantifi-
cation was 0.3 g/ml.
Data acquisition. In the acute group, the 20 s of VF before
each DFT determination shock was recorded at baseline
and after amiodarone administration. In the chronic group,
after all other electrophysiologic tests were completed on
day 30, four VF episodes separated by at least 5 min were
induced and recorded for 20 s before a rescue shock was
given. Unipolar electrograms were amplified, bandpass fil-
tered between 0.5 and 500 Hz and sampled at 2 kHz. Data
for 1-s intervals beginning 0 s, 5 s, 10 s, 15 s and 20 s after
VF induction and for a 4-s interval beginning 15 s after
Abbreviations and Acronyms
APD  action potential duration
DFT  defibrillation threshold
DI  diastolic interval
DMSO  dimethyl sulfoxide
ECG  electrocardiogram
ERP  effective refractory period
VERP  ventricular effective refractory period
VF  ventricular fibrillation
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induction were transferred to a computer workstation (Sun
Microsystems Inc., Mountain View, California) for analysis.
Quantitative analysis of VF activation. The method of
analysis of VF activation pattern has been previously de-
scribed in detail (9,10,17,18). In brief, activation patterns
during VF were quantified by first identifying individual
wavefronts (17). From the wavefronts, the following 10
descriptors were computed for each 1-s data set:
1. Number of wavefronts: The number of wavefronts com-
pletely or partially within the mapped region during the
1-s interval (17).
2. Area swept out by the wavefronts: The mean number of
electrodes that record activation from a wavefront
multiplied by the area of the plaque represented by each
electrode (4 mm2 for our 2-mm interelectrode spacing)
(17). When re-entry was present, electrodes were only
counted once. Thus, the maximum area that could be
swept out by a wavefront was the area of the plaque.
3. Fractionation incidence: Fraction of wavefronts that
fragment into two or more child wavefronts (17).
4. Collision incidence: Fraction of wavefronts that collide
and coalesce with one or more other wavefronts (17).
5. Block incidence: Fraction of wavefronts that block. Block
was identified when a wavefront terminated without
fractionating, colliding with other wavefronts or prop-
agating out of the mapped region (10).
6. Breakthrough or focal incidence: A wavefront appearing
on the epicardium in the mapped region without arising
from a fractionation or collision or without propagating
in from an edge of the mapped region. This is the
logical opposite of block. Such wavefronts have either
broken through to the epicardium from deeper layers or
have arisen de novo (10).
7. Repeatability: A cross-correlation technique was used to
sort the wavefronts into clusters. Each cluster represents
a distinct activation pathway (18). Repeatability is the
average number of wavefronts in each cluster and
expresses how many wavefronts traverse each distinct
pathway (10).
8. Overall activation rate: The mean number of wavefronts
passing each epicardial site during the 1-s interval (10).
9. Negative peak dV/dt of VF activations: The mean rapid-
ity of the downslope of activation, which may be related
to the ability of the activation front to excite adjacent
tissue.
10. Propagation speed of the wavefronts: The mean speed of
the centroids of the wavefronts (10).
Algorithms also automatically identified and quanti-
fied sequences of wavefronts that formed at least one
cycle of re-entry (9). In this analysis wavefronts are
grouped into families consisting of wavefronts con-
nected temporally by fragmentation or collision events.
If a family contained a sequence of wavefronts that
activated tissue more than once, it was deemed re-
entrant. From this analysis we computed three addi-
tional parameters for the 4-s interval beginning 15 s
after VF induction (9).
11. Incidence of re-entry: The fraction of families containing
a re-entrant sequence of wavefronts.
12. Number of re-entry cycles: The mean number of cycles of
the re-entrant circuits.
13. Core perimeter: The mean perimeter of the cores of the
re-entrant circuits calculated from the path of the inner
tip of the detected wavefronts (9).
The mean wavelength was approximated by taking the
product of the mean propagation speed of the wavefronts
and activation interval. The VF activation interval was
defined as the reciprocal of the activation rate. The activa-
tion interval is thought to be correlated with the VERP
during VF (14).
Statistical analysis. Results are expressed as mean  SD.
In both groups, VERP and DFT at baseline and after
amiodarone or placebo administration were compared by
paired t tests. In the chronic group, the 10 VF descriptors
computed by use of 1-s data intervals were compared by
three-way multivariate analysis of variance. The main inde-
pendent variable was animal group (chronic amiodarone or
control); episode number and time after VF induction were
used as blocking variables. In the acute group, we tested for
an overall pre-post amiodarone difference in the VF descrip-
tors for every data epoch using doubly multivariate repeated
measures analysis of variance. We further tested for pre-post
amiodarone differences in each of these individual parame-
ters by computing the 95% Bonferroni confidence intervals.
The three re-entry parameters in both groups were com-
pared by unpaired t tests. For all analyses p 0.05 was
considered statistically significant.
RESULTS
DFT. In the chronic group, the DFTs were not signifi-
cantly different between the amiodarone and control sub-
Table 1. Defibrillation Thresholds (Voltage) in Chronic and
Acute Amiodarone Groups
Chronic Amiodarone
(n  12)
Acute Amiodarone
(n  12)
Control
(n  6)
Amiodarone
(n  6)
Control
(n  6)
Amiodarone
(n  6)
Baseline 365  60 368  38 307  101 327  73
Treatment 366  57 389  54 311  85 348  104
Table 2. Effective Refractory Periods in Chronic and Acute
Amiodarone Groups
Chronic Amiodarone
(n  12)
Acute Amiodarone
(n  12)
Control
(n  6)
Amiodarone
(n  6)
Control
(n  6)
Amiodarone
(n  6)
Baseline 150  20 157  25 162  7 170  14
Treatment 154  29 201  14* 159  13 172  12
*p  0.05 compared with baseline.
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Figure 1. Snapshots of re-entrant activation during ventricular fibrillation (VF) episodes in control (A), acute (B) and chronic amiodarone (C) animals. Each
colored pixel is an electrode site at which dV/dt 0.5 V/s sometime during the 5-ms interval represented by each frame. The black numbers show the time in
milliseconds from the onset of the analysis interval for the corresponding frame 15 s after VF induction. Different colored pixels indicate distinct isolated
wavefronts with re-entrant circuits shown in red. The arrows indicate the direction of wavefront movements. The re-entrant wavefronts rotate counterclockwise
in A and C and clockwise in B. The core perimeter in A is smaller than in B or C. The wavefronts are more fragmented and complex in A than in B or C.
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groups either before or after treatment (Table 1). Similarly,
in the acute group, the DFT before and after treatment was
not significantly different in either the amiodarone or the
control animals.
VERP. Chronic amiodarone prolonged the VERP by 28%
(Table 2). Acute amiodarone, however, did not significantly
change the VERP.
Quantitative analysis of VF activation patterns. Ex-
amples of VF activation sequences in control, acute and
chronic amiodarone animals are shown in Figure 1. Quan-
titative data from all 1-s intervals are pooled in Tables 3 and
4. There were significant overall multivariate differences
between the chronic amiodarone and control groups (p 
0.001) and between the recordings before and after acute
amiodarone (p  0.001).
NUMBER OF WAVEFRONTS. Chronic amiodarone reduced
the number of wavefronts by 60% compared with the
control group (Table 3), and acute amiodarone reduced the
number of wavefronts by 42% compared with baseline
(Table 4). Chronic amiodarone reduced the number of
wavefronts more than acute amiodarone (p  0.05). There
was no significant difference in the number of wavefronts for
the control animals before and after intravenous DMSO/
saline (vehicle) administration (Table 4).
AREA SWEPT OUT AND REPEATABILITY. Chronic and acute
amiodarone increased the mean epicardial area swept out by
each wavefront by 40% and 45%, respectively. Chronic
amiodarone increased repeatability by 43%, while acute
amiodarone increased it by 54%.
BLOCK AND BREAKTHROUGH/FOCAL INCIDENCE. Block
incidence was increased 52% by chronic amiodarone but was
decreased 22% by acute amiodarone. The breakthrough/
focal incidence was increased 50% by chronic amiodarone
but was decreased 21% by acute amiodarone.
ACTIVATION RATE AND CONDUCTION VELOCITY. Chronic
amiodarone decreased the activation rate and conduction
velocity by 30% and 22%, respectively (Table 3). However,
acute amiodarone did not significantly change either mea-
sure (Table 4).
FRACTIONATION AND COLLISION INCIDENCE. Chronic
amiodarone significantly reduced the incidence of fraction-
ation and collision by 35% and 47%, respectively, while
acute amiodarone did not change either measure.
RE-ENTRY. Re-entry incidence was significantly reduced by
57% and 44% for chronic and acute amiodarone, respec-
tively. Chronic and acute amiodarone increased the re-
entrant core perimeter by 39% and 16% and re-entry cycle
length by 45% and 22%.
WAVELENGTH. Chronic amiodarone increased the esti-
mated wavelength by 12%, while acute amiodarone did not
significantly change it.
SERUM DRUG CONCENTRATIONS. Six dogs with chronic
amiodarone and three dogs with placebo had serum amio-
darone concentrations measured. The mean serum amioda-
Figure 1. Continued.
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rone concentration was 0.62  0.08 g/ml in the dogs
receiving chronic amiodarone and 0.3 g/ml in the
animals receiving placebo.
DISCUSSION
Effect of amiodarone on the DFT and ERP. Both acute
intravenous amiodarone and chronic oral amiodarone have
been reported to increase (3), cause no change (4) or even
decrease (5) the DFT in animal studies. One study reported
the DFT increase with amiodarone was plasma-
concentration dependent (3), while another reported that
the DFT increase was not concentration dependent (19).
An increased DFT with amiodarone has also been reported
to be associated with a monophasic, but not a biphasic,
defibrillation waveform (20). This study, which used only
one amiodarone dosage and a biphasic defibrillation wave-
form, found no change in DFT with either acute intrave-
nous or chronic oral amiodarone. While the serum level in
this study was relatively low with respect to the high doses
administered, it has been shown to create myocardial
concentrations high enough to alter cardiac electrophysi-
ologic properties (21,22). The mechanism responsible for
the different DFT effects of amiodarone in different studies
are unknown but may be related to the different experimen-
tal models, defibrillation waveforms and time and dosages of
amiodarone administration (23).
Consistent with most previous studies, the ERP, mea-
sured by an S1-S2 method with a long basic drive interval,
was significantly increased in the chronic amiodarone group
but not in the acute amiodarone group (24). The VF cycle
length in this study, which was used as an index of the VF
refractory period (14), was also increased in the chronic
amiodarone group but not in the acute amiodarone group.
While these data are consistent with prolongation of the
ERP during VF by chronic amiodarone administration,
they do not definitely prove it because increased cycle length
could also be caused by an increased excitable gap (25).
The different effects of acute and chronic amiodarone on
activation patterns during VF. Most previous studies have
demonstrated that the electrophysiologic effects of long-
term amiodarone administration are more numerous and
striking than with short-term intravenous administration
(1), but the basis for such differences has not been estab-
Table 3. Ventricular Fibrillation Activation Pattern Descriptors in Chronic Amiodarone Group
Control Group
(n  6)
Amiodarone Group
(n  6) % Change p Value
Number of wavefronts 102  45 41  21 60%2 0.001
Area swept out (mm2) 233  47 326  145 40%1 0.001
Fractionation incidence 0.17  0.07 0.11  0.07 35%2 0.0001
Collision incidence 0.17  0.06 0.09  0.06 47%2 0.0001
Block incidence 0.21  0.12 0.32  0.14 52%1 0.001
Breakthrough/focal incidence 0.20  0.13 0.30  0.14 50%1 0.001
Repeatability 5.1  1.3 7.3  1.8 43%1 0.001
Activation rate (s1) 8.3  2.2 5.8  1.7 30%2 0.001
Peak dV/dt (V/s) 3.52  1.89 1.85  0.45 47%2 0.0001
Speed (m/s) 0.54  0.1 0.42  0.18 22%2 0.0001
Reentry incidence 0.076  0.06 0.033  0.05 57%2 0.0001
Number of re-entry cycles 1.88  1.34 1.25  0.56 34%2 0.002
Reentry perimeter (mm) 44  23 61  31 39%1 0.0001
Wavelength (mm) 65  9 73  10 12%1 0.0001
Table 4. Ventricular Fibrillation Activation Pattern Descriptors in Intravenous Amiodarone Group
Control Group (n  6) Amiodarone Group (n  6)
Baseline Vehicle % Change p Baseline Treat % Change p
Number of wavefronts 101  42 96  42 5%2 NS 90  43 52  23 42%2 0.001
Area swept out (mm2) 229  47 240  45 5%1 NS 244  43 356  133 45%1 0.001
Fractionation incidence 0.16  0.06 0.17  0.06 6%1 NS 0.17  0.08 0.16  0.09 6%2 NS
Collision incidence 0.18  0.05 0.17  0.06 6%2 NS 0.17  0.07 0.16  0.06 6%2 NS
Block incidence 0.21  0.1 0.19  0.1 10%2 NS 0.18  0.07 0.14  0.11 22%2 0.001
Breakthrough/focal incidence 0.21  0.1 0.21  0.13 0% NS 0.19  0.11 0.15  0.12 21%2 0.01
Repeatability 4.8  1.1 5.2  1.4 8%2 NS 4.6  0.8 7.1  2.0 54%1 0.001
Activation rate (s1) 8.1  1.9 8.1  2.4 0% NS 7.0  1.8 6.8  1.5 4%2 NS
Peak dV/dt (V/s) 3.47  1.5 3.29  1.4 5%2 NS 3.59  2.01 3.45  1.88 4%2 NS
Speed (m/s) 0.54  0.07 0.55  0.07 2%1 NS 0.56  0.1 0.58  0.14 7%1 NS
Reentry incidence 0.071  0.05 0.068  0.06 4%2 NS 0.064  0.04 0.036  0.05 44%2 0.01
Number of re-entry cycles 1.93  1.36 1.96  1.77 2%1 NS 1.79  1.75 1.67  1.52 7%2 NS
Re-entry perimeter (mm) 41  21 42  18 2%1 NS 43  17 50  19 16%1 0.04
Wavelength (mm) 67  12 68  13 1%1 NS 80  14 85  12 6%1 NS
NS  nonsignificant.
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lished. Consistent with those studies, we found significant
changes in all of the electrophysiologic variables we exam-
ined for chronic amiodarone, but significant changes oc-
curred in less than half these variables for acute amiodarone.
For example, VERP and VF cycle length were prolonged
with chronic amiodarone but not with acute amiodarone.
Both chronic and acute amiodarone administration re-
duced the number of VF activation wavefronts, increased
the area activated by each wavefront and increased the
repeatability of the activation sequences. However, chronic
amiodarone decreased the incidence of fractionation and
collision and increased the incidence of conduction block
and of the breakthrough/focus pattern, while acute amio-
darone decreased the incidence of conduction block and of
the breakthrough/focal pattern without significantly chang-
ing the other two variables.
Many of the changes caused by chronic amiodarone may
be explained by its prolongation of the refractory period.
This includes the decreased activation rate and the de-
creased number of wavefronts during VF. There are two
possible explanations for the increased incidence of epicar-
dial breakthrough after chronic amiodarone: first, increased
focal origin of wavefronts and, second, increased transmural
orientation of wavefronts arising by re-entry. Amiodarone
has been shown to inhibit abnormal automaticity of both
Purkinje fibers and ventricular myocardium (26,27). Recent
studies demonstrate that chronic amiodarone reduces the
dispersion of repolarization both in human and animal
hearts by decreasing M cell action potential duration
(28,29). The reduction of transmural heterogeneity of re-
polarization may facilitate transmural wavefront propaga-
tion. A wavefront that appears to “block” from epicardial
mapping recordings may turn perpendicular to the epicar-
dial surface and propagate deep towards the endocardium.
So the second explanation is more likely than the first. If so,
the increased incidence of block on the epicardium after
chronic amiodarone is also consistent with an increase in
transmural orientation of wavefronts.
Acute amiodarone, which is also antiarrhythmic (24), did
not lengthen the refractory period nor change many of the
measured variables as did chronic amiodarone. Yet, acute
amiodarone increased the organization of VF by several
measures including a decreased number of wavefronts, an
increased area of epicardium activated by each wavefront, an
increased repeatability of activation sequences and a de-
creased incidence of conduction block. Acute amiodarone
has been shown to flatten the slope of the restitution curve
(30), which may explain these findings during VF. The
restitution hypothesis of VF states that the slope of the
action potential duration (APD) restitution curve, in which
APD is plotted against the preceding diastolic interval (DI),
is the main determinant of wave break (31). When the slope
of this curve is steep (1) over a sufficient range of DIs,
small perturbations in DI will be amplified into larger
differences in APD. These APD differences create larger
differences in the following DI. If this oscillation in APD
grows large enough, action potential failure occurs, causing
wave break (32). No data are available about how chronic
amiodarone, which increased the incidence of conduction
block, affects the restitution properties of myocardium.
However, other electrophysiologic properties, which are
likely to be affected by drugs such as conduction velocity or
cell coupling, also contribute to the development and
maintenance of VF (32,33).
The effects of acute and chronic amiodarone on re-entry
during VF. While VF is almost universally thought to be
maintained by re-entry (34), only 2% to 8% of wavefronts
have been identified as parts of re-entry circuits (9,35,36).
Whether VF is maintained by multiple wavelets (37,38) or
a single “mother” rotor (35), wavelength prolongation (39)
or prevention of conduction block (40) may explain the
mechanisms of most drugs’ antifibrillatory actions. The
number of wavefronts is thought to decrease as the wave-
length increases, making it more likely that VF will not be
maintained (39). However, some drugs with marked anti-
arrhythmic effects do not prolong wavelength (40). For
example, one of these drugs, procainamide, has been shown
to prevent conduction block and reduce the number of VF
wavefronts (40), which is assumed to inhibit VF mainte-
nance. This assumption is supported by clinical data (41)
demonstrating that procainamide converts polymorphic
ventricular tachycardia or VF to monomorphic ventricular
tachycardia. Recently, widening of the excitable gap has
been proposed to explain the mechanism of antifibrillation
drugs for atrial fibrillation (42). Widening of the excitable
gap will lower the chance that fibrillation wavefronts en-
counter areas of partially refractory tissue. As a result,
slowing of conduction and fractionation of wavefronts will
occur less frequently, and fibrillation may not be main-
tained.
We found that both acute intravenous and chronic oral
amiodarone markedly decreased the incidence of re-entry
during VF, but by different mechanisms. With chronic
amiodarone, the increased VERP and decreased VF activa-
tion rate suggest that wavelength was prolonged. The
increased wavelength also may be responsible for the in-
creased perimeter of the core of the re-entrant circuits after
chronic amiodarone.
After acute amiodarone administration, the absence of
significant changes in VERP, VF rate and conduction
velocity suggests that the wavelength was unchanged. Thus,
an increased wavelength is not always needed for VF to
show an increased organization by several measures includ-
ing decreased incidence of re-entry, increased perimeter of
re-entry cores, decreased re-entry cycle length, decreased
number of wavefronts, increased area activated by each
wavefront, repeatability of activation sequences, decreased
incidence of conduction block and decreased incidence of a
breakthrough/focal activation pattern. It is possible that
these changes were caused by an increased excitable gap (42)
and/or a decrease in the slope of the restitution curve (32).
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Study limitations. One limitation of the study is that only
normal healthy dogs were studied. Most patients with
arrhythmias have organic heart disease, which can affect the
patterns of activation during VF (12). It is unclear whether
the different effects of acute and chronic amiodarone are
directly applicable to VF in patients with heart disease. A
second limitation is that we studied only one dosage of
amiodarone in each group and only one treatment duration
in the chronic group. Because the action of amiodarone is
concentration- and time-dependent (43,44), studies with
different drug concentrations and different time periods are
needed. A third limitation is that transmural recordings
were not made. Such recordings are needed to determine if
the findings on the epicardium are similar to those of the
endocardium and midwall. A fourth limitation is that we
used indirect methods to estimate the refractory period and
wavelength during VF (VERP during pacing and activation
rate during VF) that do not account for differences in the
restitution curves or the excitable gap with and without
amiodarone. Optical or mean atrial pressure recordings can
provide more direct information.
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